# High-Dose Gemcitabine, Busulfan, and Thiotepa Followed by ASCT in Primary Central Nervous System Lymphoma

> **NCT07014943** · PHASE2 · RECRUITING · sponsor: **Sichuan University** · enrollment: 34 (estimated)

## Conditions studied

- Primary Central Nervous System Lymphoma (PCNSL)

## Interventions

- **DRUG:** High dose Gemcitabine, Busulfan, and Thiotepa as conditioning therapy

## Key facts

- **NCT ID:** NCT07014943
- **Lead sponsor:** Sichuan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-01-01
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 34 (ESTIMATED)
- **Last updated:** 2025-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07014943

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07014943, "High-Dose Gemcitabine, Busulfan, and Thiotepa Followed by ASCT in Primary Central Nervous System Lymphoma". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT07014943. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*